Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk, Hims & Hers Health Shares React to Lawsuit
Pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) revealed today it is pursing legal action against Hims & Hers Health Inc (NYSE:HIMS) for alleged patent infringement, after the telehealth giant introduced a weight-loss pill with the same active ingredient as its Wegovy drug -- priced at $149 -- at a much lower starting price of $49.
FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims
The Food and Drug Administration said Novo Nordisk's TV advertisement for its newly launched Wegovy pill for obesity included "false or misleading" claims about the medicine's abilities and benefits to patients. In a letter to Novo dated Feb. 5, the FDA requested that the drugmaker take immediate action to address the violations, which could include ceasing all ads containing misleading claims.
FDA says Novo's obesity pill TV Ad is false or misleading
The Food and Drug Administration said a television advertisement for Novo Nordisk's weight loss pill is "false or misleading", according to a letter dated February 5.
5 Things to Know Before the Stock Market Opens
Stock futures are slightly lower this morning after a Friday rally that pushed the Dow above 50,000 for the first time; investors are preparing for a big week of earnings reports and important economic data releases; Novo Nordisk shares are rising after Hims & Hers Health said over the weekend it would pull its compounded semaglutide pill, sending shares of the telehealth company sharply lower; Kroger shares are rising on news the supermarket chain has hired a new CEO; and STMicroelectronics shares are jumping after the European chipmaker announced a deal to supply Amazon. Here's what you need to know today.
Here's why Ozempic stock is soaring today
With its moat of widely popular direct and roundabout weight-loss drugs Ozempic and Wegovy preserved, the Danish medical giant Novo Nordisk (NYSE: NVO) saw its stock price fly early on Monday, February 9.
Novo Nordisk: The Selloff Is A Blessing In Disguise
Novo Nordisk A/S remains a Strong Buy despite a sharp 2026 outlook-driven selloff, with current pricing reflecting excessive market pessimism. NVO faces near-term headwinds from U.S. pricing pressure, patent expirations, and manufacturing ramp-up delays, but underlying free cash flow and profitability remain robust. The Wegovy pill's rapid uptake and first-mover advantage, alongside CagriSema's promising efficacy, position NVO for long-term GLP-1 market leadership.
NVO, LLY Stocks Slide as HIMS Launches $49 Compounded Semaglutide Pill
HIMS shakes up the weight loss market with a $49 compounded semaglutide pill, pressuring Novo Nordisk and Eli Lilly shares and sparking FDA and legal pushback.
Citi flags lingering risks to Novo despite strong weight-loss portfolio
Citi has warned that Novo Nordisk (NYSE:NVO) inability to curb the use of compounded semaglutide may weigh on investor sentiment, despite the strength of its obesity drug portfolio. In a note following Novo's post-results meeting in London, analysts said the launch of a compounded semaglutide pill by Hims & Hers, priced at $49 to $99, posed a challenge to the company's Wegovy pill, which starts at $149.
Why Novo Nordisk stock fell 7% after a telehealth startup's announcement
Novo Nordisk's stock dove 7% on Thursday just after an announcement from a key competitor.
Novo Nordisk shares rebound as FDA targets illegal drug copies
Shares in Danish drugmaker Novo Nordisk gained 4.7% in early trading on Friday, recovering some of the previous two sessions' steep losses, after the U.S. Food and Drug Administration (FDA) pledged to address mass-marketing of unapproved drugs.
Hims & Hers launches compounded semaglutide pill as lower-cost weight loss option
Hims & Hers (NYSE:HIMS) has announced the launch of a compounded semaglutide pill designed for weight loss, providing an alternative to Novo Nordisk (NYSE:NVO)'s Wegovy. The oral treatment uses the same active ingredient as Wegovy but is formulated to improve digestion and absorption, eliminating the need for injections.
Novo Nordisk: A Game Of Price Vs. Volume
Novo Nordisk A/S maintains a Buy rating despite recent share declines and challenging FY2026 guidance. NVO faces persistent pricing pressures, margin compression, and market share loss but is betting on volume growth and pipeline expansion. NVO stock valuation is historically low at a 13.8 P/E, offering a favorable entry point for long-term investors anticipating post-2026 recovery.
